CHMP recommend market authorisation for acalabrutinib (Calquence)

This Bruton tyrosine kinase (BTK) inhibitor is intended to be licensed as monotherapy or in combination with obinutuzumab for previously untreated adult chronic lymphocytic leukaemia (CLL), or as monotherapy for adult CLL in patients who have received at least one prior therapy.

European Medicines Agency